Chiron Corporation (/ˈkaɪrɒn/ KY-ron) was an American multinational biotechnology firm based in Emeryville, California that was acquired by Novartis on April 20, 2006. It had offices and facilities in eighteen countries on five continents. Chiron's business and research was in three main areas: biopharmaceuticals, vaccines, and blood testing. Chiron's vaccines and blood testing units were combined to form Novartis Vaccines and Diagnostics, while Chiron BioPharmaceuticals was integrated into Novartis Pharmaceuticals. In 2014, Novartis completed the sale of its blood transfusion diagnostics unit to Grifols and announced agreements for the sale of its vaccines unit to GlaxoSmithKline.

Manufactures vaccines for diseases like hepatitis, influenza, rubella and typhoid fever

BiOMViS is a biotech company committed to fostering prophylactic and immunotherapeutic interventions in infectious diseases and cancer. BiOMViS provides services to external partners in a variety of research areas, including molecular and cell biology, microbial fermentation and cell culture, protein purification, immunological assays, FACS, confocal microscopy, infectious disease, and cancer models.

Glycobia, Inc. operates platform technologies to enable glycoengineering, the intentional manipulation of protein-associated sugars to alter inherent properties of proteins for research, industrial and therapeutic applications. It engages in developing glyco-engineered bacteria that are capable of attaching human or human-like sugars onto proteins. The firm provides technology for efficient production of authentic human glycoproteins in microbial cells for manufacturing and engineering of therapeutic proteins. The company was founded by Adam C. Fisher, Matthew P. DeLisa and Chang B. Hong and is headquartered in Ithaca, NY.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Jiangsu Academy of Agricultural Sciences is a Chinese private company located in Nanjing, with subsidiaries in China, that engages in agriculture research and development.

Zhanjiang Central People's Hospital is a Chinese private company located in Zhanjiang. The firm provides healthcare services.

Shandong Jiekai Biotechnology Co., Ltd., established on 2019-01-18, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Instrument sales;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Machinery sales;Mechanical equipment research and development;General machinery and equipment installation services;Communication equipment sales;Chemical product sales(No licensed chemical products);Retailing of computer software, hardware and auxiliary equipment;Wholesale of computer software, hardware and auxiliary equipment;Cosmetics Wholesale;Cosmetics Retail;Production of Class I Medical Devices(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Import and export;Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results)

Shenzhen Baina Xinzhi Life Science Co., Ltd., established on 2019-01-10, Business scope includes general business items:Domestic Trade,Import and export of goods and technology.,The licensing program is:engaged in medical technology,Pharmaceutical Technology,Biological Technology,Inspection technology,Material Technology,Technology development in the field of therapeutic technology,technology transfer,Technical Services,technical consulting,Technology Import and Export,product development,Sales and other related services;equipment,medical instruments,laboratory equipment,computer,Software and auxiliary equipment development and management.